SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TRUMP is a politics-themed digital coin built on the Solana blockchain that uses the brand of Donald Trump to foster a community-driven ecosystem. As a community-focused asset, it is designed to bridge political support with web ownership, operating within the PolitiFi sector to blend political movements with decentralized finance tools. The project's main value proposition lies in its official ties to Donald Trump’s media and business brands, which allows it to provide unique physical utility such as invitations to gala dinners and meetings at Mar-a-Lago.  The token serves as the primary currency for the officially licensed Trump Billionaires Club mobile and web game, where it is used for in-game purchases and unlocking features. By leveraging the Solana blockchain, the project ensures that these in-game actions and token transfers remain fast and cost-effective. The ecosystem remains stable through a programmatic release schedule that introduces new tokens slowly to prevent supply shocks, alongside the use of specialized market makers to maintain consistent liquidity for traders.  Holders can also participate in liquidity sharing by providing their tokens to automated systems to facilitate trading for others, often earning rewards or prizes in return. Beyond digital utility, holding a specific amount of the token is a requirement for attending exclusive real-world events, including VIP parties at Mar-a-Lago. The project is managed by the Trump Meme Team and is linked with Trump Media, with an investor base that includes a wide range of retail buyers and large holders who utilize secure custody services for their assets.

Trump For President

TRUMP CRYPTO is experiencing heightened volatility and aggressive debate among market participants as discussions center on whether the asset is a speculative opportunity or a high-risk "pump and dump" scheme. The community remains deeply divided, with bulls pointing to the token's correlation with broader political and crypto market trends while bears emphasize its significant decline from previous highs.

Sovereign frontier cloud for AI that builds  AI agents are starting to build and operate real software. Agentic organizations are starting to coordinate people, code, data, payments, and governance. Both need a cloud that is sovereign, tamperproof, and always on.  The Internet Computer is that cloud.  Built on more than USD 500 million in R&amp;D, ICP uses advanced blockchain technology and cryptography to run entire software systems end-to-end on the network: websites, apps, services, data, payments, and governance. Code and data are protected by the protocol, replicated across independent nodes, and cannot be silently changed by a cloud provider, backend operator, or attacker.  Cloud engines make this infrastructure sovereign. They let organizations run ICP-powered compute across chosen providers, locations, and jurisdictions while keeping the same tamperproof and always-on guarantees of the network.  This is the real demand ICP serves: sovereign frontier cloud for AI agents and agentic organizations. Agents can build and update software. Organizations can run rules, assets, and governance as verifiable systems. The result is software that stays online, keeps its data, and remains under the control of its owners.  Developers and AI agents can build on the Internet Computer with any AI assistant using the ICP skill library at skills.internetcomputer.org, or by creating apps through conversation with Caffeine AI.  Computation on ICP is paid for by converting $ICP into cycles. $ICP is also used for staking and governance through the Network Nervous System.

Internet Computer

Internet Computer is trending as investors debate the contrast between its long-term technological potential in AI and cloud infrastructure versus its ongoing price volatility. While some community members remain bullish on its development pace and real-world adoption, others express significant frustration over the lack of sustained price performance.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

AMGN is trending as investors rotate into blue-chip healthcare, buoyed by the company's strong earnings beat, raised guidance, and positive clinical trial data. The community is actively discussing its momentum as a defensive cornerstone, potential obesity drug catalysts, and ongoing speculation regarding strategic M&A within the biotech sector.

Mastercard, Inc. is a technology company, which engages in the provision of payment solutions for the development and implementation of credit, debit, prepaid, commercial, and payment programs through its brands including Mastercard, Maestro, and Cirrus. It also offers cyber and intelligence solutions. The company was founded in November 1966 and is headquartered in Purchase, NY.

Mastercard Incorporated - Ordinary Shares - Class A

Mastercard Inc

Mastercard is trending as investors weigh its ongoing expansion into stablecoin infrastructure and blockchain payments against broader macroeconomic concerns and AI-related disruption fears. Community sentiment remains split between long-term confidence in the company's resilient transaction-driven model and caution regarding potential regulatory headwinds and sector-wide competitive shifts.

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics is seeing heightened investor interest and extreme volatility as the community debates the long-term potential of its mRNA pipeline following recent clinical data and ongoing legal battles regarding its LUNAR delivery technology. Traders are actively discussing the company's valuation relative to its cash reserves, with many highlighting its potential as a buyout candidate or a high-upside play if upcoming milestones for its cystic fibrosis and rare disease programs succeed.

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the development of imdusiran (AB-729), proprietary, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic, and AB-101, proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). The company was founded on October 6, 2005 and is headquartered in Warminster, PA.

Arbutus Biopharma Corp

Arbutus Biopharma is trending following news that it plans to initiate a modified Dutch-auction tender offer to repurchase up to $230 million of its common shares. The community is actively debating the strategic implications of this move, specifically whether it signals management's confidence in the company's valuation, potential upcoming news, or preparation for a future buyout or settlement.

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol-Myers Squibb Co.

Bristol-Myers Squibb is seeing increased investor attention as the community weighs strong Q2 earnings and regulatory wins against lingering speculation over potential large-scale merger activity. Investors are closely tracking how the company's growth portfolio, particularly Opdivo and mezigdomide, will bridge revenue gaps created by upcoming patent expirations.

Penguin Solutions, Inc. engages in designing, building, and managing enterprise solutions. It operates through the following segments: Advanced Computing, Integrated Memory, and Optimized LED. The Advanced Computing segment offers platform solutions and services for artificial intelligence, high-performance computing, machine learning, advanced modeling, and the internet of things. The Integrated Memory refers to integrated memory solutions through the design and development. The Optimized LED segment comprises a broad portfolio of application-optimized LEDs. The company was founded in 1988 and is headquartered in Fremont, CA.

Penguin Solutions Inc.

Penguin Solutions is surging as investors cheer a significant earnings beat and raised full-year guidance driven by strong demand for its AI infrastructure and memory-efficient solutions. The stock is seeing intense activity as market participants debate whether this momentum can drive shares toward triple-digit levels or if current valuation multiples necessitate a near-term cooling period.

HeartFlow, Inc. operates as a cardiovascular company which engages in diagnosing coronary artery diseases. The firm provides a patient-specific analysis of coronary blood flow utilizing coronary CT scans and proprietary computer algorithms based on computational fluid dynamics. The company was founded by Charles A. Taylor, Nathan M. Wilson, and Christopher K. Zarins in July 2007 and is headquartered in Mountain View, CA.

Heartflow Inc

Heartflow, Inc.

Heartflow is currently trending as investors debate whether the stock is undergoing an organic breakout or a heavily manipulated pump, with many pointing to suspicious volume patterns and an overdue pullback. Sentiment remains deeply divided between long-term believers in the company's AI cardiac technology and traders bracing for a potential share offering due to the stock's elevated valuation and insider selling.

Direxion Shares ETF Trust - Direxion Daily Junior Gold Miners Index Bull 2X ETF

JNUG is trending as investors react to gold's continued momentum, which is being fueled by broader concerns over U.S. fiscal deficits, rising bond yields, and ongoing economic uncertainty. The community is actively debating the sustainability of the current rally while pointing to technical charts and macro instability as potential catalysts for further price action.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Best Momentum Stocks to Buy for August 21st

LITE, ONTO and ASMB made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 21st, 2026.

New Strong Buy Stocks for August 21st

MCY, ASMB, ONTO, BSET and UNH have been added to the Zacks Rank #1 (Strong Buy) List on August 21st, 2026.

Are You Looking for a Top Momentum Pick? Why Assembly Biosciences (ASMB) is a Great Choice

Does Assembly Biosciences (ASMB) have what it takes to be a top stock pick for momentum investors? Let's find out.

Wall Street Analysts Think Assembly Biosciences (ASMB) Could Surge 40.66%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 40.7% in Assembly Biosciences (ASMB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Assembly Biosciences (ASMB) Reports Q2 Loss, Beats Revenue Estimates

Assembly Biosciences (ASMB) delivered earnings and revenue surprises of +71.43% and +45.37%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

BridgeBio Pharma (BBIO) Reports Q2 Loss, Tops Revenue Estimates

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -21.88% and +9.46%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Assembly Biosciences (ASMB) Reports Q1 Loss, Misses Revenue Estimates

Assembly Biosciences (ASMB) delivered earnings and revenue surprises of +26.03% and -10.73%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Assembly Biosciences' (ASMB) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reissued a "buy" rating and issued a $50.00 price objective on shares of Assembly Biosciences in a research note on Monday...

Assembly Biosciences (ASMB) Projected to Post Quarterly Earnings on Thursday

Assembly Biosciences (NASDAQ:ASMB) will be releasing its Q1 2026 earnings after the market closes on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-assembly-biosciences-inc-stock...

Assembly Biosciences, Inc. (NASDAQ:ASMB) Receives Consensus Rating of "Moderate Buy" from Brokerages

Assembly Biosciences, Inc. (NASDAQ:ASMB - Get Free Report) has been assigned an average rating of "Moderate Buy" from the seven ratings firms that are presently covering the company, Marketbeat...

Assembly Biosciences, Inc. is a biotechnology company that focuses on developing small molecule antiviral therapeutics for serious viral diseases. Its lead programs, ABI-5366 and ABI-1179, long-acting helicase-primase inhibitors, are in clinical development for recurrent genital herpes. The company is partnered with Gilead Sciences to advance current and future antiviral programs across herpesviruses, HBV, and HDV. Assembly Biosciences was founded in 2005 and is headquartered in South San Francisco, CA.

Assembly Biosciences Inc

Assembly Biosciences Stock Jumps After Wall Street Says Gilead Opt-In ‘Significantly De-Risks’ Genital Herpes Programs

Equity

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info